Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGLBiotechnology
-$1.33 today
- Market cap
- $9.25B
- Beta
- -1.06
- P/E (TTM)
- -46.9
- EPS (TTM)
- -$10.66
Volume 0.64M
Average 0.31M
MDGL Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin widens to -15.9%
Net margin was -15.9% in Q2 FY2026, up 4.0 pp from a year earlier. On a trailing-twelve-month basis it was -25.3%, up 29.4 pp year over year.
What to watch
Whether net margin reaches the consensus estimate from 12 analysts of -4.1% for the fiscal year ending Dec 2026, up from -30.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -15.9%+14.4 pp QoQ
- Last fiscal yearDec 2025
- -30.1%+228.6 pp YoY
- LTMJun 2026
- -25.3%+29.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.0 pp | +33.3 pp | +29.3 pp |
| 1 year | +228.6 pp | +26.0 pp | -202.6 pp |
| 3 years | — | +43.6 pp | — |
| 5 years | +54.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -30.1%
- Year-over-year change
- +228.6pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -30.1% | +228.6pp |
| FY2024 | 2024-12-31 | -258.6% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Net Margin vs competitors
How MDGL compares with its peers on the latest reported figures
- MDGL's LTM Jun 2026 net margin of -25.3% is the highest of the 5 companies compared; the peer median is -5616.0%.
- Its year-over-year change of +29.4 pp is the 2nd highest of 5, against a peer median of -2014.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | -25.3% | +29.4 pp | — | |
| LTM Mar 2026 | -612.7% | -643.7 pp | — | |
| LTM Jun 2026 | -3644.2% | -3385.3 pp | -883.7 pp | |
| FY2025 | -7587.8% | -5585.1 pp | -7142.2 pp | |
| LTM Mar 2026 | -253002.8% | +198197.2 pp | -339438.9 pp | |
| FY2025 | — | — | — | |
SGMTSagimet Biosciences Inc. | FY2025 | — | — | — |
| Peer median (excluding MDGL) | -5616.0% | -2014.5 pp | -7142.2 pp | |
Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 180.13M | 958.4M |
| Cost of Revenue | 0 | 0 | 0 | 6.23M | 56.15M |
| Gross Profit | 0 | 0 | 0 | 173.9M | 902.26M |
| Gross Margin | — | — | — | 96.5% | 94.1% |
| Research & Development | 205.16M | 245.44M | 272.35M | 236.72M | 388.53M |
| Selling, General & Admin | 37.32M | 48.13M | 108.15M | 435.06M | 813.83M |
| Operating Expenses | 242.48M | 293.57M | 380.5M | 671.78M | 1.2B |
| Depreciation & Amortization | 405K | 467K | 527K | 1.1M | 1.51M |
| EBITDA | (241.44M) | (290.92M) | (360.39M) | (450.13M) | (264.47M) |
| EBITDA Margin | — | — | — | -249.9% | -27.6% |
| Operating Income | (242.48M) | (293.57M) | (380.5M) | (497.88M) | (300.1M) |
| Operating Margin | — | — | — | -276.4% | -31.3% |
| Interest Income | 363K | 2.19M | 19.58M | 46.65M | 37.36M |
| Interest Expense | 0 | 3.96M | 12.71M | 14.67M | 22.31M |
| Other Income / Expenses | 636K | (1.78M) | 6.87M | 31.98M | 11.81M |
| Income Before Tax | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Pre-Tax Margin | — | — | — | -258.6% | -30.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Net Margin | — | — | — | -258.6% | -30.1% |
| EPS (Basic) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| EPS (Diluted) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| Weighted Avg Shares | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
| Weighted Avg Shares (Diluted) | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
Intrinsic Alpha fair value
Locked
Current Price
$398.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.